Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission

Reuters

2025/09/11

Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission

Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA™ Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086686), on September 11, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566999635"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566999635\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566999635?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566999635","market":"us","top_or_hot":-1,"title":"Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA™ Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086686), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA™ Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086686), on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL6yS1rG:1","article_id":"2566999635","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566999635","pubTimestamp":1757597448,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4539":"次新股","IINN":"Inspira Technologies Oxy B.H.N. Ltd."},"translate_title":"Inspira Technologies宣布HYLA准确率达到97.3%™血液传感器测试，为FDA提交铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IINN":0.9},"content_text":"Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission\n    \n\n        Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA™ Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086686), on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}